Header Artwork
Header Artwork

ON-DEMAND WEBINAR

ON-DEMAND WEBINAR

When drug meets device: How to assess compatibility?

Published Date: February 13, 2020

The frequent contact of patients with combined products, a concept that describes the joint use of drugs and devices, makes the assessment of the compatibility of a device with certain drugs a very important topic. In this webinar, Dr. Lise Vanderkelen and Dr. Ruth Verplaetse talk passionately about the necessity of a good relationship between the drug and the device for the benefit of the patient. Determining the compatibility of combined products includes many different aspects. All these aspects need to be in balance to establish a healthy relationship within the combined products and to avoid any danger that may harm a patient. This webinar will particularly focus on drug stability, chemical compatibility and biocompatibility.

During this 40-minute webinar, you will learn about:

  • The regulations & practical applications of combined products
  • The different aspects of drug-device compatibility assessment in general
  • The theoretic procedures behind the determination of drug stability, chemical compatibility and biocompatibility
Lise Vanderkelen

Lise Vanderkelen

PhD
Pharmaceuticals and Microbiology Expert

Lise Vanderkelen received her Ph.D. from the Faculty of Bioscience Engineering at the University of Leuven (Belgium) in 2012. She started at Nelson Labs Europe in 2013 as Study Director Extractables & Leachables, focusing on parenteral applications, and in 2014, she became responsible for the chemical characterization testing of medical devices (ISO 10993-18). In 2016,...

Ruth Verplaetse, PhD

Ruth Verplaetse received her PhD from the Faculty of Pharmaceutical Sciences at the University of Leuven (Belgium) in 2011. Afterwards, Ruth was active in the field of development and validation of bioanalytical methods with LC-MS/MS. She started at Nelson Labs Europe (formerly Toxikon Europe) in 2016 as study director at the Extractables & Leachables department. In 2017, she became part of the Pharma Services Department where she is involved in identifying organic impurities in drug products, stability testing of drug-device combinations as well as development and validation of analytical methods.

Complete the following information to access the webinar